Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • rayank7777777 rayank7777777 Dec 12, 2013 5:47 PM Flag

    SNTA from SA article

    SNTA is working on several drug candidates that have been discovered and developed internally in SNTA's labs and has HUGE potential for investors.

    Why Synta?

    SNTA possesses a unique chemical compound library, consisting of proprietary compounds collected over two decades from industrial and academic sources that are not typically found at pharmaceutical firms, even larger more well-known pharmaceutical behemoths. Using this library of compounds, researchers use a variety of biochemical and molecular techniques to generate and optimize promising lead compounds and generate new drug candidates that can enter the drug development process. Most compounds do not make it past the preliminary stages, but some of the most successful drugs will, eventually leading to human trials and full blown randomized clinical trials. As an epidemiologist, I am very familiar with this process. SNTA currently has an impressive 800 issued patents and pending applications worldwide. SNTA's leading candidate drug is the anti-breast, colorectal, lung and hemolytic cancer drug ganetespib, which has real potential to come to market.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I did not realize they have so many patents and pending applications !

      Why Synta?

      SNTA possesses a unique chemical compound library, consisting of proprietary compounds collected over two decades from industrial and academic sources that are not typically found at pharmaceutical firms, even larger more well-known pharmaceutical behemoths. Using this library of compounds, researchers use a variety of biochemical and molecular techniques to generate and optimize promising lead compounds and generate new drug candidates that can enter the drug development process. Most compounds do not make it past the preliminary stages, but some of the most successful drugs will, eventually leading to human trials and full blown randomized clinical trials. As an epidemiologist, I am very familiar with this process. SNTA currently has an impressive 800 issued patents and pending applications worldwide. SNTA's leading candidate drug is the anti-breast, colorectal, lung and hemolytic cancer drug ganetespib, which has real potential to come to market. It has been studied in over 900 patients in over 20 clinical trials.

      Sentiment: Strong Buy

 
SNTA
0.3430.000(0.00%)Jul 22 3:59 PMEDT